As for SVA, today's news and the weak general markets worked at cross purposes... but so goes September (and October). That said, the news was really all about a corporate update for Sernova if the details were understood enough. The SVA markets have been starved for information. Looks like Sernova's longtime buddy, ViaCyte, will Virtually run the show.
Sernova to also present Corporate Update as part of Company Presentations
London, Ontario - TheNewswire - September 10, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announced today that Dr. Philip Toleikis, President and CEO, will be a member of the Cell and Gene Therapies for Chronic Conditions panel at the virtual 2020 Cell & Gene Meeting on the Mesa. The panel session will be available on-demand to attendees as of Thursday, October 15, 2020. Dr. Toleikis will also provide an update on Sernova's clinical and research programs as part of the 2020 Company Presentations segment of the conference.
The panel will discuss the latest developments in Cell and Gene therapies for chronic conditions and will be moderated by Paul Laikind, Ph.D., President, and CEO of ViaCyte, Inc. In addition to Drs. Toleikis and Laikind, panelists are Pavan Cheruvu, M.D., CEO, Axovant Gene Therapies; Jane Lebkowski, Ph.D., President of R&D, Regenerative Patch Technologies, Inc.; and Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics.
The panel will also participate in one of only two daily Live Streaming Sessions with Questions and Answers from participants on October 13, 2020 from 12:00 - 1:00pm PST.
Sernova's Corporate Update presentation will be available on-demand to attendees of the Virtual Cell & Gene Meeting on the Mesa throughout the conference. For more details on the panel and Sernova's presentation, please visit www.meetingonthemesa.com .